Literature DB >> 25792005

Improved precision of exposure-response relationships by optimal dose-selection. Examples from studies of receptor occupancy using PET and dose finding for neuropathic pain treatment.

Matts Kågedal1, Mats O Karlsson, Andrew C Hooker.   

Abstract

An understanding of the relationship between drug exposure and response is a fundamental basis for any dosing recommendation. We investigate optimal dose-selection for two different types of studies, a receptor occupancy study assessed by positron emission tomography (PET) and a dose-finding study in neuropathic pain treatment. For the PET-study, an inhibitory E-max model describes the relationship between drug exposure and displacement of a radioligand from specific receptors in the brain. The model has a mechanistic basis in the law of mass action and the affinity parameter (Ki PL ) is of primary interest. For optimization of the neuropathic pain study, the model is empirical and the exposure response curve itself is of primary interest. An alternative parameterization of the sigmoid Emax model was therefore used where the plasma concentration corresponding to the minimum relevant efficacy was estimated as a parameter. Optimal design methodology was applied using the D-optimal criterion as well as the Ds-optimal criterion where parameters of interest were defined. For the PET-study it was shown that the precision of Ki PL can be improved by inclusion of brain regions with both high and low receptor density and that the need for high doses is reduced when a brain region with low receptor density is included in the analysis. In the case of the neuropathic pain study it was shown that a Ds-optimal study design using the reparameterized Emax model can improve the precision in the minimum effective dose compared to a D-optimal design.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25792005     DOI: 10.1007/s10928-015-9410-8

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  18 in total

1.  POPED, a software for optimal experiment design in population kinetics.

Authors:  Marco Foracchia; Andrew Hooker; Paolo Vicini; Alfredo Ruggeri
Journal:  Comput Methods Programs Biomed       Date:  2004-04       Impact factor: 5.428

2.  Robust population pharmacokinetic experiment design.

Authors:  Michael G Dodds; Andrew C Hooker; Paolo Vicini
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-02       Impact factor: 2.745

3.  Optimal designs for estimating the interesting part of a dose-effect curve.

Authors:  Frank Miller; Olivier Guilbaud; Holger Dette
Journal:  J Biopharm Stat       Date:  2007       Impact factor: 1.051

Review 4.  Consensus nomenclature for in vivo imaging of reversibly binding radioligands.

Authors:  Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2007-05-09       Impact factor: 6.200

5.  Optimizing disease progression study designs for drug effect discrimination.

Authors:  Sebastian Ueckert; Stefanie Hennig; Joakim Nyberg; Mats O Karlsson; Andrew C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-08-27       Impact factor: 2.745

6.  Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited.

Authors:  Vincent J Cunningham; Eugenii A Rabiner; Mark Slifstein; Marc Laruelle; Roger N Gunn
Journal:  J Cereb Blood Flow Metab       Date:  2009-09-09       Impact factor: 6.200

7.  Benzodiazepine receptor quantification in vivo in humans using [11C]flumazenil and PET: application of the steady-state principle.

Authors:  N A Lassen; P A Bartenstein; A A Lammertsma; M C Prevett; D R Turton; S K Luthra; S Osman; P M Bloomfield; T Jones; P N Patsalos
Journal:  J Cereb Blood Flow Metab       Date:  1995-01       Impact factor: 6.200

8.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography.

Authors:  M A Mintun; M E Raichle; M R Kilbourn; G F Wooten; M J Welch
Journal:  Ann Neurol       Date:  1984-03       Impact factor: 10.422

Review 9.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

10.  Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.

Authors:  L Farde; A L Nordström; F A Wiesel; S Pauli; C Halldin; G Sedvall
Journal:  Arch Gen Psychiatry       Date:  1992-07
View more
  2 in total

1.  Optimizing Dose-Finding Studies for Drug Combinations Based on Exposure-Response Models.

Authors:  Theodoros Papathanasiou; Anders Strathe; Rune Viig Overgaard; Trine Meldgaard Lund; Andrew C Hooker
Journal:  AAPS J       Date:  2019-07-29       Impact factor: 4.009

2.  Feasibility of Exposure-Response Analyses for Clinical Dose-Ranging Studies of Drug Combinations.

Authors:  Theodoros Papathanasiou; Anders Strathe; Andrew C Hooker; Trine Meldgaard Lund; Rune Viig Overgaard
Journal:  AAPS J       Date:  2018-04-23       Impact factor: 4.009

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.